A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

NCT04119453 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
80
Enrollment
INDUSTRY
Sponsor class

Stopped The RM-202 study was terminated by the Sponsor due to redirection of the rivoceranib development plan.

Conditions

Interventions

Sponsor

Elevar Therapeutics